@article{pmid16203159,

title = {Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study},

author = {A Prinster and M Quarantelli and G Orefice and R Lanzillo and A Brunetti and C Mollica and E Salvatore and V Brescia Morra and G Coppola and G Vacca and B Alfano and M Salvatore},

doi = {10.1016/j.neuroimage.2005.08.034},

issn = {1053-8119},

year  = {2006},

date = {2006-02-01},

journal = {Neuroimage},

volume = {29},

number = {3},

pages = {859--867},

abstract = {Global grey matter (GM) loss has been reported in multiple sclerosis (MS). We addressed the question of if and where GM loss is localized by means of optimized voxel-based morphometry, applied to MRI studies of 51 patients with clinically defined relapsing-remitting MS and 34 age-matched normal subjects, segmented into normal and abnormal brain tissues using a multiparametric approach. Segmented GM volumes were subsequently compared on a voxel-by-voxel basis to highlight regions of relative GM loss (P < 0.05, corrected for multiple comparisons at AnCova). Additionally, localized differences in brain asymmetry between the MS and the control groups were assessed by comparing on a voxel-by-voxel basis maps of GM differences between the two hemispheres (P < 0.05 corrected for multiple comparisons). In MS patients, GM volume was significantly decreased at the level of the left fronto-temporal cortex and precuneus, as well as of anterior cingulate gyrus and of caudate nuclei bilaterally. The only cortical region of significant GM loss in the right hemisphere was located in the postcentral area. Furthermore, GM loss regions were colocalized with increased GM asymmetries (Left < Right) in MS, confirming a preferential left-sided GM loss. Caudate atrophy correlated with lesion load, while no correlation between cortical regional GM loss and disease duration, clinical status or lesion load emerged. Our findings suggest that in RR-MS cortical GM reduction preferentially involves left fronto-temporal structures and deep GM, the latter correlating preferentially to global lesion load.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid16051375,

title = {The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis},

author = {Francesco Lolli and Benedetta Mazzanti and Marta Pazzagli and Elisa Peroni and Maria Claudia Alcaro and Giuseppina Sabatino and Roberta Lanzillo and Vincenzo Brescia Morra and Lucio Santoro and Claudio Gasperini and Stefania Galgani and Mario Milco D'Elios and Valentina Zipoli and Stefano Sotgiu and Maura Pugliatti and Paolo Rovero and Mario Chelli and Anna Maria Papini},

doi = {10.1016/j.jneuroim.2005.05.016},

issn = {0165-5728},

year  = {2005},

date = {2005-10-01},

journal = {J Neuroimmunol},

volume = {167},

number = {1-2},

pages = {131--137},

abstract = {Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs (p<0.001) or versus other autoimmune diseases (SLE or RA, p<0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies to CSF114(Glc) is a new, potential immunological marker of MS.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid15742102,

title = {Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation},

author = {Giovanni Coppola and Chiara Criscuolo and Giuseppe De Michele and Salvatore Striano and Fabrizio Barbieri and Pasquale Striano and Anna Perretti and Lucio Santoro and Vincenzo Brescia Morra and Francesco Saccà and Valentina Scarano and Adamo P D'Adamo and Sandro Banfi and Paolo Gasparini and Filippo M Santorelli and Anna E Lehesjoki and Alessandro Filla},

doi = {10.1007/s00415-005-0766-3},

issn = {0340-5354},

year  = {2005},

date = {2005-08-01},

journal = {J Neurol},

volume = {252},

number = {8},

pages = {897--900},

abstract = {We describe two couples of sibs from a southern Italian family affected by epilepsy, myoclonus, mental retardation and slight ataxia. Onset was between 4 and 12 years and the course slowly progressive. The clinical picture suggested the diagnosis of Unverricht-Lundborg disease. Molecular study excluded linkage to EPM1. Other possible causes of progressive myoclonus epilepsy were also excluded.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid14716527,

title = {Epileptic seizures in multiple sclerosis: clinical and EEG correlations},

author = {P Striano and G Orefice and V Brescia Morra and P Boccella and C Sarappa and R Lanzillo and G Vacca and S Striano},

doi = {10.1007/s10072-003-0183-2},

issn = {1590-1874},

year  = {2003},

date = {2003-12-01},

journal = {Neurol Sci},

volume = {24},

number = {5},

pages = {322--328},

abstract = {Epileptic seizures occur more frequently in multiple sclerosis (MS) patients than in the general population. We evaluated clinical, electroencephalographic (EEG) and magnetic resonance imaging (MRI) findings, as well as EEG-MRI correlations and the response to antiepileptic drugs (AEDs) in 270 consecutive patients with definite MS referred to our Department from 1995 to 2002. Thirteen (4.8%) subjects experienced epileptic seizures. In four cases, seizures manifested within 1-2 years ("early-onset"), and in six cases within 8-23 years ("late-onset") of MS diagnosis. Seizures were usually partial with secondary generalization. Thus, acute symptomatic seizures occurred in three cases. Epilepsy usually appeared late in the course of disease, although a single episode or a cluster of seizures can represent the onset symptom or a relapse of MS. Prognosis of epilepsy during the course of MS is usually good but the choice of AEDs remains a matter of debate.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid12595189,

title = {Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load},

author = {Mario Quarantelli and Andrea Ciarmiello and Vincenzo Brescia Morra and Giuseppe Orefice and Michele Larobina and Roberta Lanzillo and Vittorio Schiavone and Elena Salvatore and Bruno Alfano and Arturo Brunetti},

doi = {10.1016/s1053-8119(02)00018-6},

issn = {1053-8119},

year  = {2003},

date = {2003-02-01},

journal = {Neuroimage},

volume = {18},

number = {2},

pages = {360--366},

abstract = {The aim of this study was to simultaneously measure in vivo volumes of gray matter (GM), normal white matter (WM), abnormal white matter (aWM), and cerebro-spinal fluid (CSF), and to assess their relationship in 50 patients with relapsing-remitting multiple sclerosis (RR-MS) (age range, 21-59; mean EDSS, 2.5; mean disease duration, 9.9 years), using an unsupervised multiparametric segmentation procedure applied to brain MR studies. Tissue volumes were normalized to total intracranial volume providing corresponding fractional volumes (fGM, faWM, fWM, and fCSF), subsequently corrected for aWM-related segmentation inaccuracies and adjusted to mean patients' age according to age-related changes measured in 54 normal volunteers (NV) (age range 16-70). In MS patients aWM was 23.8 +/- 29.8 ml (range 0.4-138.8). A significant decrease in fGM was present in MS patients as compared to NV (49.5 +/- 3.2% vs 53.3 +/- 2.1%; P < 0.0001), with a corresponding increase in fCSF (13.0 +/- 3.8% vs 9.1 +/- 2.4%; P < 0.0001). No difference could be detected between the two groups for fWM (37.5 +/- 2.6% vs 37.6 +/- 2.2%). faWM correlated inversely with fGM (R = -0.434, P < 0.001 at regression analysis), and directly with fCSF (R = 0.473, P < 0.001), but not with fWM. There was a significant correlation between disease duration and EDSS, while no relationship was found between EDSS or disease duration and fractional volumes. Brain atrophy in RR-MS is mainly related to GM loss, which correlates with faWM. Both measures do not appear to significantly affect EDSS, which correlates to disease duration.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid12235496,

title = {Aphasia as a rare presentation of monosymptomatic demyelinating disease: case report and review of the literature},

author = {L Di Majo and M Bisceglia and R Lanzillo and V D'Angelo and L Gorgoglione and L Chiacchio and G Orefice},

doi = {10.1007/s100720200030},

issn = {1590-1874},

year  = {2002},

date = {2002-06-01},

journal = {Neurol Sci},

volume = {23},

number = {2},

pages = {79--82},

abstract = {We present a case of sudden-onset aphasia due to a single pathological lesion, which at neuroradiological imaging studies was suggestive of glioma, while on biopsy proved be of demyelinating nature. Every cause of demyelinating lesions of the central nervous system was considered in the differential diagnosis, concluding for a primary demyelinating disease. The clinical and radiological differences between multiple sclerosis and acute disseminated encephalomyelitis are discussed. Although aphasia has already been described in demyelinating diseases, we underline its rarity as onset symptom.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid11739812,

title = {HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis},

author = {C Fusco and V Andreone and G Coppola and V Luongo and F Guerini and E Pace and C Florio and G Pirozzi and R Lanzillo and P Ferrante and P Vivo and M Mini and M Macrì and G Orefice and M L Lombardi},

doi = {10.1212/wnl.57.11.1976},

issn = {0028-3878},

year  = {2001},

date = {2001-12-01},

journal = {Neurology},

volume = {57},

number = {11},

pages = {1976--1979},

abstract = {BACKGROUND: Copolymer 1 (Cop-1) is a random synthetic amino acid copolymer, effective in the treatment of the relapsing-remitting form of MS (RRMS). In vitro and in vivo studies suggest that the mechanism of Cop-1 involves its binding to major histocompatibility complex class II molecules as an initial step.nnOBJECTIVE: To assess a possible relationship between human leukocyte antigen (HLA) alleles and response to Cop-1 therapy.nnMETHODS: Eighty-three patients with RRMS, 44 treated with Cop-1 and 39 with interferon beta-1a (IFNbeta-1a) for 2 years, were typed by molecular methods for HLA class II genes and subgrouped according to clinical outcome.nnRESULTS: Data have shown a possible positive correlation between presence of DRB1*1501 and response to Cop-1 therapy (p = 0.008). No relationship between HLA alleles and therapy has been found in IFNbeta-1a treated patients.nnCONCLUSIONS: Results suggest that DRB1*1501 might be relevant for the clinical outcome in Cop-1 treated patients and, if confirmed in larger studies, it could be helpful in the selection of RRMS patients for different therapeutic options.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}